135795-46-9Relevant articles and documents
BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF
-
Page/Page column 42; 43, (2018/05/15)
The invention provides novel compounds having the general formula (I) wherein R1, X, Zlto Z5, L, n, the A ring, and the B ring, are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.Compounds (I) act as inhibitors of RIP1 kinase.
Preparation of azaindolines and benzoyl substituted azaindolines: Precursors of triazabenzo[cd]azulen-9-one PDE4 inhibitors
Badland, Matthew,Devillers, Ingrid,Durand, Corinne,Fasquelle, Véronique,Gaudillire, Bernard,Jacobelli, Henry,Manage, Ajith C.,Pevet, Isabelle,Puaud, Jocelyne,Shorter, Anthony J.,Wrigglesworth, Roger
supporting information; experimental part, p. 5292 - 5296 (2011/10/30)
The syntheses of various substituted azaindolines are described. Azaindolines were identified as potential key intermediates towards new PDE4 inhibitors.
1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO
-
Page/Page column 170-171, (2010/02/11)
Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.